The Part 11 Controversy: A Root Cause Analysis and Science-Based Solutions

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-06-01-2005, Volume 205 Supplement, Issue 3

The confusion surrounding the application of 21 CFR Part 11 can be solved by focusing on the common rationale that both protects the public health and drives the fundamental basis of the industry's business: good science.

Related Content:

Quality SystemsInformation TechnologyPharmaceutical Technology-06-01-2005
Regulatory Collaboration on Mpox Treatments Summarized in Report
Retrofitting Facilities for Cell and Gene Therapy Production
What Does the FDA's Recent Update of the Nitrosamine Guidance Convey?